Friday, June 28, 2013
Access Pharmaceuticals Inc., of Dallas, said top-line results from a Phase IV study showed that Mugard mucoadhesive oral wound rinse met the primary study endpoint, with patients receiving the product experiencing a statistically significant reduction vs. placebo in mouth and throat soreness.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.